Kura Oncology Plans Wider Platform Study for Darlifarnib Amid Recent Data on Anti-Tumor Activity

Data ReadoutpositiveDarlifarnibPositive

AI Analysis

Summary

Kura Oncology announced plans for a wider platform study of Darlifarnib following recent data demonstrating anti-tumor activity. The company is expanding its clinical development strategy for the candidate.

Clinical Trial Data

Outcome Details

Anti-tumor activity demonstrated

Importance:5/10

Sentiment:

0.60

darlifarniboncologyplatform studyanti-tumor activity

Related Companies

$KURA

Read the original article

Published by yahoo_finance on June 3, 2026 11:53 AM

Read Original